A Phase 3 interventional study of Rituximab SC and Rituximab IV in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 152 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-27.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 12th largest by enrollment of the 171 interventional ones that give a count, is one of 6 that started in 2011, is one of 29 in phase 3, and was the 118th registered.
2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:
Paolo Caimi, MD · Sites in United States
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
University of Cologne · Sites in Germany
Ages 18–99
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
M.D. Anderson Cancer Center · Sites in United States
Ages 15–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
178 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 112 · Phase 3 30 · Phase 4 5
First in 1995; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 410 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 38 across the 171 interventional studies. Of the 152 that completed or were terminated, 80 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 178 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche: 1 open now, 6 under way, 1 of them phase 3. Of 47 finished, 22 (47%) have results posted.
Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 49 interventional ones that give a count, is one of 6 that started in 2011, is one of 11 in phase 3, and was the 18th registered.
Hoffmann-La Roche’s Lymphoma, Non-Hodgkin studies by the year they started, since 1997.
4 of the studies testing rituximab in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05583071University of CologneMethotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | 2027-02 |
| NCT01829958Memorial Sloan Kettering Cancer CenterComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | 2027-04 |
| NCT02727803M.D. Anderson Cancer CenterPersonalized NK Cell Therapy in CBT | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, from their registry updates:
Among Hoffmann-La Roche’s 54 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
This two-stage, multi-center, randomized, controlled, open-label study will investigate the pharmacokinetics, efficacy and safety of rituximab SC versus rituximab IV in participants with previously untreated follicular non-Hodgkin's lymphoma. Participants will be randomized to receive 375 milligrams per meter square (mg/m\^2) rituximab as IV infusion or 1400 milligrams (mg) rituximab SC. In addition, participants will receive standard chemotherapy. Participants who achieved a complete or partial response (PR) after 8 treatment cycles, will receive maintenance treatment for a further maximum number of 12 cycles. Maintenance treatment cycles will be repeated every 8 weeks. This is a two-stage study. Stage 1 was designed to confirm the chosen rituximab SC dose resulting in comparable rituximab serum Ctrough levels compared with rituximab IV, when given as part of induction treatment every 3 weeks. Enrollment for Stage 2 started after the rituximab SC dose was established in Stage 1. Stage 2 aimed to further investigate the efficacy and safety of rituximab SC compared with rituximab IV. The anticipated time on study treatment is 96 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) in combination with up to 8 cycles of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) or cyclophosphamide, vincristine, prednisolone (CVP) chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.
Drug: Rituximab IV · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone/Prednisolone
First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
Drug: Rituximab SC · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone/Prednisolone
First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
Also known as: MabThera
Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.
Also known as: MabThera
Eight cycles of cyclophosphamide (750 mg/m\^2 IV) administered every 3 weeks.
Eight cycles of doxorubicin (50 mg/m\^2 IV) administered every 3 weeks.
Eight cycles of doxorubicin (1.4 mg/m\^2 IV) administered every 3 weeks.
Drug pages: Prednisone · Prednisolone
Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m\^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab
Time frame: Stage I: Cycle (Cy) 7 Day (D) 21 (within 2 hours predose on Cy8) of induction treatment (1 Cy=3 weeks)
Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for Non-Hodgkin Lymphoma (NHL)
Overall Response comprised complete response (CR), CR unconfirmed (CRu), or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and computed tomography (CT) scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by more than (\>) 75% in the sum of the products of greatest diameters (SPD); PR: Greater than or equal to (≥) 50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper.
Time frame: Stage II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)
Stage I: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
Overall Response comprised CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in the SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper.
Time frame: Stage I: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)
Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
Overall Response comprised of CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.
Time frame: Stage I and II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)
Stage I: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
Complete Response was comprised CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.
Time frame: Stage I: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)
Stage II: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.
Time frame: Stage II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)
Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.
Time frame: Stage I and II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)
Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL
Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.
Time frame: Stage I and II: Baseline up to 57 days after last maintenance dose (last maintenance dose: maintenance Cy12/Study Cy20 [30 months]) (up to data cutoff of 31 Oct 2017 [up to 6 years]) (1 Cy=8 weeks)
Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL
Overall Response comprised of CR, CRu, or PR . A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.
Time frame: Stage I and II: Baseline up to 57 days after last maintenance dose (last maintenance dose: maintenance Cy12/Study Cy20 [30 months]) (up to data cutoff of 31 Oct 2017 [up to 6 years]) (1 Cy=8 weeks)
Stage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse or Death
Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node \>1 cm in its short axis or in the SPD of more than one node. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])
Time frame: Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)
Stage I and II (Pooled): Progression-Free Survival (PFS) Assessed Using International Working Group Response Criteria for NHL
PFS was defined as the time from randomization to disease progression/relapse or death due to any cause. If the specified event (disease progression/relapse, death) did not occur, PFS was censored at the last tumor assessment date showing no disease progression, either during treatment or follow-up. Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node \>1 cm in its short axis or in the SPD of more than one node. PFS analysis was performed using Kaplan - Meier curves. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])
Time frame: Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)
Stage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse, New Anti-Lymphoma Treatment or Death Assessed Using International Working Group Response Criteria for NHL
Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node \>1 cm in its short axis or in the SPD of more than one node. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to a median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])
Time frame: Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)
Stage I and II (Pooled): Event-Free Survival Assessed Using International Working Group Response Criteria for NHL
Event-free survival was defined as the time from randomization to disease progression/relapse, death or initiation of new NHL therapy. If the specified event (progression/relapse, death or new anti-lymphoma treatment) did not occur, event-free survival was censored at the last tumor assessment date either during treatment or follow up. Event-free survival analysis was performed using Kaplan-Meier curves. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to a median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])
Time frame: Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)
Percentage of Participants Who Died
Time frame: Baseline up to death (up to data cutoff of 31 Oct 2017 [up to 6 years])
Overall Survival (OS)
OS was defined as the time from randomization to death due to any cause. Participants without event were censored at the time of last follow-up information for survival, ie, at the last time known to be alive.
Time frame: Baseline up to death (up to data cutoff of 31 Oct 2017 [up to 6 years])
Stage I: Observed Area Under the Serum Concentration-Time Curve (AUC) of Rituximab
AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Predose (within 2 hr) and 24 hrs postdose on Cy 7 (D1,3,7,15), predose (0 hr) on Cy 8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion (infusion duration=30 minutes) on Cy 7 D1 for rituximab IV (up to data cutoff of 11 Apr 2012 \[up to 26 months\])
Time frame: Stage I (Induction): Predose (within 2 hour [hr]) up to data cutoff of 11 Apr 2012 [up to 26 months]) (See detailed timeframe in Outcome Measure description)
Stage I: Maximum Serum Concentrations (Cmax) of IV and SC Rituximab
Predose (within 2 hr) and 24 hrs postdose on Cy7 (D1,3,7,15), predose (0 hr) on Cy8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion (infusion duration=30 minutes) on Cy7 D1 for rituximab IV (up to data cutoff of 11 Apr 2012 \[up to 26 months\])
Time frame: Stage I (Induction): Predose (within 2hr) up to data cutoff of 11 Apr 2012 [up to 26 months]) (See detailed timeframe in Outcome Measure description)
Stage I and II (Pooled): Ctrough of Rituximab at Each Induction Treatment Cycle
Stage I and II (Induction): Rituximab IV: Predose (within 2 hr) on D1 of Cy1-8 (1 Cy=3 weeks \& 4 weeks for Cy8); Rituximab SC: Predose (within 2 hr) on D1 of Cy1 \& Cy3-8 (1 Cy=3 weeks and 4 weeks for Cy8), predose (within 2 hr) on D0 of Cy2 (up to data cutoff of 31 Oct 2013 \[up to 32 months\])
Time frame: Stage I and II (Pooled): Predose (within 2hr) up to data cutoff of 31 Oct 2013 [up to 32 months]) (See detailed timeframe in Outcome Measure description)
Stage I and II (Pooled): Ctrough of Rituximab at Each Maintenance Treatment Cycle
Stage I and II (maintenance): D29 of Cy8 (induction; 1 Cy=4 weeks), predose (within 2 hr) on D1 of Cy9 to 19 (maintenance Cy1 to 12 \[1 Cy=8 weeks\]; up to data cutoff of 11 Jan 2016 \[up to 6 years\])
Time frame: Stage I and II (maintenance): Predose (within 2hr) up to data cutoff of 11 Jan 2016 [up to 6 years]) (See detailed timeframe in Outcome Measure description)
Stage I and II (Pooled): Rituximab Levels 12 Weeks, 24 Weeks, and 36 Weeks After the Last Rituximab Administration
Time frame: 12 weeks, 24 weeks, and 36 weeks after the last rituximab administration (up to data cutoff of 11 Jan 2016 [up to 6 years])
Percentage of Participants With B-Cell Depletion by Cycle for Induction Phase
Depletion is defined as a cluster of differentiation (CD) 19 value \<80 cells per cubic millimeter (cells/mm\^3).
Time frame: Stage I and II (induction): for rituximab IV - D1 of Cy 1 to 8 (1 Cy=3 weeks); for rituximab SC - D1 of Cy 1 and Cy 3 to 8, D0 of Cy 2
Percentage of Participants With B-Cell Depletion by Cycle for Maintenance Phase
Depletion is defined as a CD19 value \<80 cells/mm\^3.
Time frame: Stage I and II (maintenance): D1 of Cy 9 to 20 (1 Cy=8 weeks) (up to data cutoff of 11 Jan 2016 [up to 6 years])
Stage I and II (Pooled): Percentage of Participants Positive for Human Anti-Chimeric Antibodies (HACAs) to Rituximab
Levels of HACA in serum were detected at Day 1 of each cycle up to Cycle 8 and at follow-up visit. Stage I and II: Baseline: pre-dose (72 hours prior) D1 of Cy1, Cy 3-20, D0 of Cy2 (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), post-baseline: every 12 weeks after last rituximab administration until 96 weeks (a median of 27 months; up to data cutoff of 11 Jan 2016 \[up to 6 years\])
Time frame: Stage I and II: Baseline, post-baseline (See detailed timeframe in Outcome Measure description)
Stage I and II (Pooled): Percentage of Participants Positive for Human Anti-Human Antibodies (HAHAs) to Rituximab
Levels of HAHA in serum were detected at Day 1 of each cycle up to Cycle 8 and at follow-up visit. Stage I and II: Baseline: pre-dose (72 hours prior) D1 of Cy1, Cy 3-20, D0 of Cy2 (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), post-baseline: every 12 weeks after last rituximab administration until 96 weeks (a median of 27 months; up to data cutoff of 11 Jan 2016 \[up to 6 years\])
Time frame: Stage I and II: Baseline, post-baseline (See detailed timeframe in Outcome Measure description)
Stage I and II (Pooled): Percentage of Responses Showing Time Saved of Staff as Per Physician/Nurse Opinions With Each Administration of Rituximab SC as Compared to Rituximab IV at the End of Cy 8, 15 and 20
All investigator physicians and nurses involved in this study were asked to provide the staff time that could be saved with each administration of rituximab SC as compared with rituximab IV to participants in routine practice afetr Cy 8, 15, 20 and categorized as less than (\<) 1 hr, at least 1 hr but \<2 hrs, at least 2 hrs but \<3 hrs, at least 3 hrs but \<4 hrs, \>/=4 hrs. Staff were asked not to consider the time needed for the first IV administration. Analysis was done in all participants to show a comparison on the time saved by staffs when administered via SC and IV.
Time frame: After Cycle 8 of induction treatment (24 weeks) and during the maintenance part of the study after 12 months (i.e., Cycle 15), and after the end of the maintenance treatment, (i.e., Cycle 20) (1 Cycle=4 weeks for Cycle 8 and 8 weeks for Cycles 15 and 20)
Percentage of Responses Who Showed Rituximab SC Formulation Convenient as Compared to Rituximab IV Formulation as Assessed by Physician/Nurse Opinion
All investigator physicians and nurses involved in this study were asked to complete question i.e. "Which formulation of rituximab (SC or IV) do you think is more convenient?" based on their experience with the rituximab SC and IV formulations across all participants and presented as rituximab SC is much more convenient; rituximab SC is a little more convenient; both formulations are equally convenient; rituximab IV is a little more convenient; and rituximab IV is much more convenient.
Time frame: After Cycle 8 of induction treatment (24 weeks) and during the maintenance part of the study after 12 months (i.e., Cycle 15), and after the end of the maintenance treatment, (i.e., Cycle 20) (1 Cycle=4 weeks for Cycle 8 and 8 weeks for Cycles 15 and 20)
| Milestone | Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) | Stage II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|---|---|
| Started | 64 | 63 | 0 | 0 |
| Completed | 46 | 46 | 0 | 0 |
| Not completed | 18 | 17 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 1 | 0 | 0 |
| Withdrew: Adverse event | 5 | 5 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 0 |
| Withdrew: Disease progression | 9 | 7 | 0 | 0 |
| Milestone | Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) | Stage II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|---|---|
| Started | 0 | 0 | 141 | 142 |
| Completed | 0 | 0 | 100 | 92 |
| Not completed | 0 | 0 | 41 | 50 |
| Withdrew: Disease progression | 0 | 0 | 16 | 21 |
| Withdrew: Lack of efficacy | 0 | 0 | 4 | 2 |
| Withdrew: Physician decision | 0 | 0 | 5 | 7 |
| Withdrew: Adverse event | 0 | 0 | 5 | 9 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 4 |
| Withdrew: Death | 0 | 0 | 3 | 5 |
| micrograms per milliliter (mcg/mL) | Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab | 83.1 ± 36.7 | 134.6 ± 43.2 |
Overall Response comprised complete response (CR), CR unconfirmed (CRu), or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and computed tomography (CT) scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by more than (\>) 75% in the sum of the products of greatest diameters (SPD); PR: Greater than or equal to (≥) 50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper.
| percentage of participants | Stage II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for Non-Hodgkin Lymphoma (NHL) | 85.1 (78.1 to 90.5) | 80.3 (72.8 to 86.5) |
Overall Response comprised CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in the SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper.
| percentage of participants | Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage I: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL | 82.8 (71.3 to 91.1) | 90.5 (80.4 to 96.4) |
Overall Response comprised of CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.
| percentage of participants | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL | 84.9 (79.2 to 89.5) | 84.4 (78.7 to 89.1) |
Complete Response was comprised CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.
| percentage of participants | Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage I: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL | 25.0 (15.0 to 37.4) | 42.9 (30.5 to 56.0) |
Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.
| percentage of participants | Stage II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage II: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL | 34.8 (26.9 to 43.2) | 28.2 (20.9 to 36.3) |
Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.
| percentage of participants | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL | 31.7 (25.4 to 38.6) | 32.2 (25.9 to 39.1) |
Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.
| percentage of participants | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL | 57.9 (50.3 to 65.2) | 50.6 (42.9 to 58.3) |
Overall Response comprised of CR, CRu, or PR . A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.
| percentage of participants | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL | 78.1 (71.3 to 83.9) | 77.9 (71.0 to 83.9) |
Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node \>1 cm in its short axis or in the SPD of more than one node. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])
| percentage of participants | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse or Death | 34.6 | 31.7 |
PFS was defined as the time from randomization to disease progression/relapse or death due to any cause. If the specified event (disease progression/relapse, death) did not occur, PFS was censored at the last tumor assessment date showing no disease progression, either during treatment or follow-up. Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node \>1 cm in its short axis or in the SPD of more than one node. PFS analysis was performed using Kaplan - Meier curves. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])
| days | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage I and II (Pooled): Progression-Free Survival (PFS) Assessed Using International Working Group Response Criteria for NHL | NA (NA to NA) | NA (NA to NA) |
Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node \>1 cm in its short axis or in the SPD of more than one node. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to a median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])
| percentage of participants | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse, New Anti-Lymphoma Treatment or Death Assessed Using International Working Group Response Criteria for NHL | 36.1 | 35.1 |
Event-free survival was defined as the time from randomization to disease progression/relapse, death or initiation of new NHL therapy. If the specified event (progression/relapse, death or new anti-lymphoma treatment) did not occur, event-free survival was censored at the last tumor assessment date either during treatment or follow up. Event-free survival analysis was performed using Kaplan-Meier curves. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to a median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])
| days | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage I and II (Pooled): Event-Free Survival Assessed Using International Working Group Response Criteria for NHL | NA (2126 to NA) | NA (NA to NA) |
| percentage of participants | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Percentage of Participants Who Died | 12.7 | 8.8 |
OS was defined as the time from randomization to death due to any cause. Participants without event were censored at the time of last follow-up information for survival, ie, at the last time known to be alive.
| days | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Predose (within 2 hr) and 24 hrs postdose on Cy 7 (D1,3,7,15), predose (0 hr) on Cy 8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion (infusion duration=30 minutes) on Cy 7 D1 for rituximab IV (up to data cutoff of 11 Apr 2012 \[up to 26 months\])
| mcg*day/mL | Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage I: Observed Area Under the Serum Concentration-Time Curve (AUC) of Rituximab | 2734.21 ± 32.51 | 3778.93 ± 37.59 |
Predose (within 2 hr) and 24 hrs postdose on Cy7 (D1,3,7,15), predose (0 hr) on Cy8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion (infusion duration=30 minutes) on Cy7 D1 for rituximab IV (up to data cutoff of 11 Apr 2012 \[up to 26 months\])
| mcg/mL | Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Stage I: Maximum Serum Concentrations (Cmax) of IV and SC Rituximab | 250.63 ± 19.66 | 236.82 ± 31.45 |
Stage I and II (Induction): Rituximab IV: Predose (within 2 hr) on D1 of Cy1-8 (1 Cy=3 weeks \& 4 weeks for Cy8); Rituximab SC: Predose (within 2 hr) on D1 of Cy1 \& Cy3-8 (1 Cy=3 weeks and 4 weeks for Cy8), predose (within 2 hr) on D0 of Cy2 (up to data cutoff of 31 Oct 2013 \[up to 32 months\])
| mcg/mL | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Cycle 1 (n = 198, 193) | 14.00 ± 157.53 | 12.88 ± 189.70 |
| Cycle 2 (n = 197, 190) | 30.13 ± 145.36 | 40.00 ± 124.50 |
| Cycle 3 (n = 192, 190) | 45.25 ± 110.35 | 63.83 ± 101.83 |
| Cycle 4 (n = 186, 185) | 54.06 ± 108.90 | 81.71 ± 92.28 |
| Cycle 5 (n = 185, 185) | 64.68 ± 89.90 | 98.00 ± 71.91 |
| Cycle 6 (n = 187, 180) | 71.02 ± 87.60 | 109.56 ± 58.74 |
| Cycle 7 (n = 183, 172) | 78.31 ± 77.76 | 120.75 ± 55.60 |
| Cycle 8 (n = 52, 54) | 77.60 ± 70.53 | 131.48 ± 50.20 |
Stage I and II (maintenance): D29 of Cy8 (induction; 1 Cy=4 weeks), predose (within 2 hr) on D1 of Cy9 to 19 (maintenance Cy1 to 12 \[1 Cy=8 weeks\]; up to data cutoff of 11 Jan 2016 \[up to 6 years\])
| mcg/mL | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Cycle 8 (n = 174, 170) | 37.69 ± 94.30 | 61.31 ± 65.52 |
| Cycle 9 (n = 171, 168) | 30.35 ± 75.03 | 49.47 ± 81.23 |
| Cycle 10 (n = 164, 160) | 28.44 ± 84.64 | 47.27 ± 73.03 |
| Cycle 11 (n = 164, 157) | 28.77 ± 65.28 | 46.70 ± 66.80 |
| Cycle 12 (n = 160, 150) | 28.80 ± 56.97 | 44.72 ± 68.74 |
| Cycle 13 (n = 157, 150) | 28.84 ± 54.04 | 44.32 ± 67.67 |
| Cycle 14 (n = 153, 147) | 28.09 ± 55.61 | 43.32 ± 67.97 |
| Cycle 15 (n = 148, 143) | 28.19 ± 52.69 | 44.11 ± 67.92 |
| Cycle 16 (n = 150, 145) | 28.05 ± 57.19 | 42.96 ± 64.32 |
| Cycle 17 (n = 149, 143) | 28.24 ± 57.51 | 42.82 ± 65.67 |
| Cycle 18 (n = 143, 132) | 28.59 ± 62.06 | 44.79 ± 68.56 |
| Cycle 19 (n = 138, 131) | 27.75 ± 78.26 | 43.69 ± 69.02 |
| mcg/mL | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Week 12: Follow-up Visit 1 (n = 117, 118) | 15.60 (0.70 to 80.40) | 22.35 (0.65 to 107.00) |
| Week 24: Follow-up Visit 2 (n = 88, 96) | 2.89 (0.58 to 17.40) | 5.19 (0.69 to 62.10) |
| Week 36: Follow-up Visit 3 (n = 38, 53) | 1.08 (0.52 to 51.40) | 2.02 (0.53 to 33.90) |
Depletion is defined as a cluster of differentiation (CD) 19 value \<80 cells per cubic millimeter (cells/mm\^3).
| percentage of participants | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Cycle 1 Day 1 - Baseline (n=188, 168) | 51.6 | 54.8 |
| Cycle 2 Day 0 (n=183, 180) | 95.1 | 95.0 |
| Cycle 3 Day 1 (n=175, 175) | 99.4 | 99.4 |
| Cycle 4 Day 1 (n=178, 180) | 99.4 | 100.0 |
| Cycle 5 Day 1 (n=179, 176) | 100.0 | 100.0 |
| Cycle 6 Day 1 (n=173, 175) | 100.0 | 100.0 |
| Cycle 7 Day 1 (n=178, 173) | 100.0 | 100.0 |
| Cycle 8 Day 1 (n=175, 174) | 100.0 | 100.0 |
Depletion is defined as a CD19 value \<80 cells/mm\^3.
| percentage of participants | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Cycle 9 Day 1 (n=170, 161) | 99.4 | 100.0 |
| Cycle 10 Day 1 (n=165, 164) | 99.4 | 100.0 |
| Cycle 11 Day 1 (n=158, 158) | 99.4 | 100.0 |
| Cycle 12 Day 1 (n=151, 146) | 100.0 | 100.0 |
| Cycle 13 Day 1 (n=149, 143) | 100.0 | 100.0 |
| Cycle 14 Day 1 (n=152, 143) | 100.0 | 100.0 |
| Cycle 15 Day 1 (n=149, 140) | 100.0 | 100.0 |
| Cycle 16 Day 1 (n=142, 141) | 100.0 | 100.0 |
| Cycle 17 Day 1 (n=145, 142) | 100.0 | 100.0 |
| Cycle 18 Day 1 (n=141, 140) | 100.0 | 100.0 |
| Cycle 19 Day 1 (n=140, 138) | 100.0 | 100.0 |
| Cycle 20 Day 1 (n=139, 134) | 100.0 | 100.0 |
Levels of HACA in serum were detected at Day 1 of each cycle up to Cycle 8 and at follow-up visit. Stage I and II: Baseline: pre-dose (72 hours prior) D1 of Cy1, Cy 3-20, D0 of Cy2 (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), post-baseline: every 12 weeks after last rituximab administration until 96 weeks (a median of 27 months; up to data cutoff of 11 Jan 2016 \[up to 6 years\])
| percentage of participants | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Baseline (n=208, 191) | 5.8 | 2.6 |
| Post-Baseline (n=206, 197) | 1.5 | 2.0 |
Levels of HAHA in serum were detected at Day 1 of each cycle up to Cycle 8 and at follow-up visit. Stage I and II: Baseline: pre-dose (72 hours prior) D1 of Cy1, Cy 3-20, D0 of Cy2 (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), post-baseline: every 12 weeks after last rituximab administration until 96 weeks (a median of 27 months; up to data cutoff of 11 Jan 2016 \[up to 6 years\])
| percentage of participants | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Baseline (n=68, 188) | 10.3 | 11.2 |
| Post-Baseline (n=66, 197) | 7.6 | 13.2 |
All investigator physicians and nurses involved in this study were asked to provide the staff time that could be saved with each administration of rituximab SC as compared with rituximab IV to participants in routine practice afetr Cy 8, 15, 20 and categorized as less than (\<) 1 hr, at least 1 hr but \<2 hrs, at least 2 hrs but \<3 hrs, at least 3 hrs but \<4 hrs, \>/=4 hrs. Staff were asked not to consider the time needed for the first IV administration. Analysis was done in all participants to show a comparison on the time saved by staffs when administered via SC and IV.
| percentage of responses | All Participants |
|---|---|
| After Cy8: <1 hour (n=166) | 11 |
| After Cy8: ≥1 to <2 hours (n=166) | 20 |
| After Cy8: ≥2 to <3 hours (n=166) | 35 |
| After Cy8: ≥3 to <4 hours (n=166) | 18 |
| After Cy8: ≥4 hours (n=166) | 16 |
| After Cy15: <1 hour (n=130) | 13 |
| After Cy15: ≥1 to <2 hours (n=130) | 17 |
| After Cy15: ≥2 to <3 hours (n=126) | 34 |
| After Cy15: ≥3 to <4 hours (n=130) | 14 |
| After Cy15: ≥4 hours (n=130) | 22 |
| After Cy20: <1 hour (n=126) | 14 |
| After Cy20: ≥1 to <2 hours (n=126) | 32 |
| After Cy20: ≥2 to <3 hours (n=126) | 21 |
| After Cy20: ≥3 to <4 hours (n=126) | 13 |
| After Cy20: ≥4 hours (n=126) | 19 |
All investigator physicians and nurses involved in this study were asked to complete question i.e. "Which formulation of rituximab (SC or IV) do you think is more convenient?" based on their experience with the rituximab SC and IV formulations across all participants and presented as rituximab SC is much more convenient; rituximab SC is a little more convenient; both formulations are equally convenient; rituximab IV is a little more convenient; and rituximab IV is much more convenient.
| percentage of responses | All Participants |
|---|---|
| Cy8: Rituximab SC much more convenient (n=166) | 81 |
| Cy8: Rituximab SC little more convenient (n=166) | 13 |
| Cy8: Both formulations equally convenient (n=166) | 2 |
| Cy8: Rituximab IV little more convenient (n=166) | 4 |
| Cy8: Rituximab IV much more convenient (n=166) | 0 |
| Cy15: Rituximab SC much more convenient (n=130) | 88 |
| Cy15: Rituximab SC little more convenient (n=130) | 7 |
| Cy15: Both formulations equally convenient (n=130) | 5 |
| Cy15: Rituximab IV little more convenient (n=130) | 0 |
| Cy15: Rituximab IV much more convenient (n=130) | 0 |
| Cy20: Rituximab SC much more convenient (n=126) | 88 |
| Cy20: Rituximab SC little more convenient (n=126) | 9 |
| Cy20: Both formulations equally convenient (n=126) | 2 |
| Cy20: Rituximab IV little more convenient (n=126) | 1 |
| Cy20: Rituximab IV much more convenient (n=126) | 0 |
Collected over Baseline up to data cutoff date of 31 Oct 2017 (up to 6 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | — | 76/210 (36.2%) | 187/210 (89%) |
| Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) | — | 74/197 (37.6%) | 186/197 (94.4%) |
| Event | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 10/210 | 12/197 |
| PneumoniaInfections and infestations | 7/210 | 11/197 |
| NeutropeniaBlood and lymphatic system disorders | 4/210 | 6/197 |
| PyrexiaGeneral disorders | 5/210 | 6/197 |
| Neutropenic sepsisInfections and infestations | 4/210 | 1/197 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/210 | 1/197 |
| SepsisInfections and infestations | 1/210 | 3/197 |
| ConstipationGastrointestinal disorders | 3/210 | 0/197 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/210 | 2/197 |
| CystitisInfections and infestations | 1/210 | 2/197 |
| Event | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) |
|---|---|---|
| NauseaGastrointestinal disorders | 47/210 | 65/197 |
| NeutropeniaBlood and lymphatic system disorders | 57/210 | 65/197 |
| ConstipationGastrointestinal disorders | 55/210 | 50/197 |
| CoughRespiratory, thoracic and mediastinal disorders | 32/210 | 49/197 |
| FatigueGeneral disorders | 38/210 | 42/197 |
| AstheniaGeneral disorders | 27/210 | 35/197 |
| DiarrhoeaGastrointestinal disorders | 35/210 | 34/197 |
| AnaemiaBlood and lymphatic system disorders | 26/210 | 30/197 |
| ParaesthesiaNervous system disorders | 27/210 | 30/197 |
| Upper respiratory tract infectionInfections and infestations | 26/210 | 30/197 |
Intent-to-Treat (ITT) Population included all participants who were randomized into study irrespective whether they received study drug or not.
| Age, Continuous(years) | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) | Total |
|---|---|---|---|
| Mean | 56.9 ± 12.69 | 56.1 ± 12.66 | 56.5 ± 12.67 |
| Sex: Female, Male(Participants) | Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) | Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) | Total |
|---|---|---|---|
| Female | 99 | 120 | 219 |
| Male | 106 | 85 | 191 |
Showing the first 100 of 152 sites across 30 countries. Choose a country and city above to see the rest.
Ran from Feb 2011 to primary completion in Jun 2012, 15 months.
Results were first posted in Aug 2015, 3 years 1 month after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 15 months is below that.
Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab